InflaRx Sets Date for Full Year 2024 Results, Announces Investor Conference Participation in March

JENA, Germany, Feb. 25, 2025 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focused on developing anti-inflammatory treatments by targeting the complement system, announced today that it will release its financial and operational results for the fourth quarter and full year 2024 on March 20, 2025. The company does not plan to hold a conference call.

InflaRx also announced its participation in two investor conferences, with the following details:

Leerink Global Healthcare Conference
March 9 – 12, 2025 in Miami Beach, FL

InflaRx will host a fireside chat at the conference on March 10 at 10:40 AM ET and will be available for one-on-one investor meetings. A registration link for the live stream and replay of the fireside chat is available .

H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 27, 2025

InflaRx will conduct a virtual fireside chat on March 27 at 8:30 AM ET and will participate in individual investor meetings. A registration link for the live stream and replay of the fireside chat is available .

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company at the forefront of developing anti-inflammatory therapies. It utilizes its proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize highly effective and specific inhibitors targeting the complement activation factor C5a and its receptor C5aR. C5a is a potent inflammatory mediator implicated in the progression of numerous inflammatory diseases. InflaRx’s leading drug candidate, vilobelimab, is a first-in-class, intravenously administered monoclonal antibody that selectively binds to free C5a. It has demonstrated disease-modifying clinical activity and tolerability across multiple clinical studies in various indications. InflaRx is also advancing INF904, an orally available, small molecule inhibitor of the C5a receptor. Founded in 2007, InflaRx has offices and subsidiaries in Jena and Munich, Germany, and Ann Arbor, MI, USA. For more information, please visit .

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (collectively, InflaRx).

Contacts:

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. All statements that are not historical facts are forward-looking statements. These statements are often identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among other similar expressions. Forward-looking statements are present throughout this release and may include statements about our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and other factors described in our periodic filings with the SEC under the headings “Risk factors” and “Cautionary statement regarding forward looking statements.” These statements are made only as of the date of this press release and are subject to known and unknown risks, uncertainties, and other important factors that could cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by the forward-looking statements. Due to these risks, uncertainties, and other factors, you should not rely unduly on these forward-looking statements. We assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

“`